Eli Lilly and Company manufactures Zepbound [1].
When did Zepbound get approved?
Zepbound received U.S. Food and Drug Administration (FDA) approval on November 8, 2023, for chronic weight management in adults with obesity or overweight with at least one weight-related condition [2].
What is Zepbound used for?
Zepbound is indicated for chronic weight management in adults who are obese (BMI of 30 or greater) or overweight (BMI of 27 or greater) and have at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia [1][2]. It is used in conjunction with diet and exercise [1].
How does Zepbound work?
Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By activating these receptors, it helps regulate appetite and food intake [1][3]. This mechanism leads to a reduction in calorie consumption and subsequent weight loss [3].
What is the active ingredient in Zepbound?
The active ingredient in Zepbound is tirzepatide [1][3]. Tirzepatide was previously approved under the brand name Mounjaro for type 2 diabetes [3].
What are the common side effects of Zepbound?
Common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite [1]. These side effects are often dose-dependent and may decrease over time [1].
Are there serious risks associated with Zepbound?
Serious risks associated with Zepbound include pancreatitis, gallbladder problems, kidney problems, serious allergic reactions, and thyroid C-cell tumors, which have been observed in animal studies [1]. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Zepbound [1].
How does Zepbound compare to other weight loss medications?
Zepbound (tirzepatide) has demonstrated significant weight loss in clinical trials, often exceeding the results seen with other currently available weight loss medications [3]. Its dual action on GIP and GLP-1 receptors is thought to contribute to its efficacy [3]. Competitors in the weight loss drug market include semaglutide (Wegovy) and liraglutide (Saxenda) [4].
What is the dosage for Zepbound?
Dosing for Zepbound starts at 5 mg once weekly and can be increased every four weeks to 10 mg or 15 mg once weekly to reach the maintenance dose that best controls appetite and weight loss [1].
How much does Zepbound cost?
The list price for Zepbound is approximately $1,059.87 for a 28-day supply [1]. However, actual costs may vary depending on insurance coverage and pharmacy [1].
When does the patent for Zepbound expire?
Drug patents are complex and can involve multiple patents covering different aspects of a drug, such as the compound itself, its manufacturing process, and its uses. Information on specific patent expiry dates for Zepbound (tirzepatide) can be found on resources like DrugPatentWatch.com [5]. Generally, brand-name drug patents can last up to 20 years from the filing date, but various extensions and legal challenges can alter the effective market exclusivity period.
Are there any alternatives to Zepbound for weight management?
Alternatives to Zepbound for weight management include other prescription medications such as semaglutide (Wegovy), liraglutide (Saxenda), and phentermine-topiramate (Qsymia) [4]. Lifestyle modifications, including diet and exercise, are also fundamental components of weight management [1].
---
1. Eli Lilly and Company. (n.d.). Zepbound™ (tirzepatide) injection. Retrieved from https://www.zepbound.lilly.com/
2. U.S. Food & Drug Administration. (2023, November 8). FDA approves new medication to treat obesity and overweight. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-medication-treat-obesity-and-overweight
3. Gizer, S. G., & Levine, J. A. (2023). Tirzepatide for the Treatment of Obesity. Current Obesity Reports, 12(4), 458–467. https://doi.org/10.1007/s13679-023-00517-5
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., Charlotte, S., et al. (2022). Once-Weekly Tirzepatide in Adults with Obesity. The New England Journal of Medicine, 387(21), 2007–2017. https://doi.org/10.1056/NEJMoa2206038
5. DrugPatentWatch.com. (n.d.). Tirzepatide. Retrieved from https://drugpatentwatch.com/